Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
Status:
Not yet recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of
age with hemorrhagic shock potentially needing significant blood transfusion.
The primary objective of the clinical trial is to determine the effectiveness of Low Titer
Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA)
compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life
threatening hemorrhage.
Phase:
Phase 3
Details
Lead Sponsor:
Philip Spinella
Collaborator:
Biomedical Advanced Research and Development Authority